Cystic Fibrosis

DISEASE SUMMARY

Definition

  • Cystic fibrosis (CF) is a severe, progressive, often life-threatening autosomal recessive disorder affecting multiple organ systems, particularly the exocrine glands.

  • Characterized by the production of abnormally viscous mucus, especially in the pancreas and lungs.

Prevalence

  • In the United States, there are nearly 30,000 patients diagnosed with CF.

  • Clinically significant manifestations occur in approximately 1 in every 3,200 to 3,500 Caucasians.

  • Carrier statistics:

    • 1 in 25 Caucasians (whites) are carriers.

    • Over 10 million adults are asymptomatic carriers of the dysfunctional gene.

  • Ethnic incidence (full-blown CF):

    • Hispanics: 1 in 9,200–9,500

    • African-Americans: 1 in 15,000–17,000

    • Asian-Americans: 1 in 31,000

    • Native Americans: 1 in 80,000

  • Carrier statistics for other ethnicities:

    • African-Americans: 1 in 62

    • Asian-Americans: 1 in 90

  • No gender preference noted, although males may experience slower pulmonary function decline for unexplained reasons.

Significance

  • CF is the most common cause of severe chronic lung disease in children and young adults and the most common fatal hereditary disorder among whites in the U.S.

  • It significantly affects multiple organ systems and often leads to early mortality, typically in childhood or early adulthood.

  • Average life expectancy for individuals with CF is about mid-30s.

CASE STUDY: CYSTIC FIBROSIS

Patient Case Overview

  • Common progressive multisystem disease characterized by:

    • Abnormal secretion of viscous mucus.

    • Severe chronic respiratory disease and pancreatic enzyme insufficiency.

    • Other complications include elevated sweat electrolytes leading to salt depletion and reduced fertility.

  • Classification:

    • Airflow obstructive disorder

    • Suppurative disease (pus-forming)

Complications of CF

  • Numerous complications arise, primarily due to progressive tissue injury:

    • Respiratory Complications: 90% of patients experience pulmonary involvement; common respiratory manifestations include:

    • Recurrent respiratory infections leading to lung damage.

    • Pseudomonas aeruginosa colonization occurs in 75% of CF children.

    • Progression to bronchitis, bronchiolitis, bronchiectasis, pneumonia, and severe outcomes like cor pulmonale and respiratory failure.

    • Gastrointestinal Complications:

    • Conditions such as cholelithiasis affect 30–35% of patients.

    • Other GI issues include pancreatitis, biliary cirrhosis, and pancreatic enzyme dysfunction (80-90% affected).

    • Diabetes (non-type 1/non-type 2) occurs after age 10 in 20% of patients.

    • Symptoms include steatorrhea, abdominal pain, constipation, and maldigestion of nutrients contributing to poor nutritional status.

    • Obstetric Issues: Congenital absence of vas deferens in 98% of male patients leading to infertility.

  • **Other Complications: **

    • Nasal polyps, chronic cough, fatigue, chronic sinus infections, and risk of certain cancers.

    • Increased risk of weak bones and arthropathies.

CAUSES AND RISK FACTORS

Genetic Basis

  • CF is inherited via an autosomal recessive trait caused by mutations in the CFTR gene located on the long arm of chromosome 7.

  • The CFTR protein is a chloride ion channel in epithelial cell membranes, activated by cyclic AMP.

  • Over 1300 mutations have been identified, with 230 mutations linked to clinical abnormalities. Notably, the F508 mutation is the most prevalent, causing 60–75% of CF cases.

Risk Factors

  • The strongest risk factor for developing CF is a positive family history of the disease, especially within families with Northern European ancestry.

  • The probability of CF manifestation increases significantly when both parents are carriers of mutations in the CFTR gene.

PATHOPHYSIOLOGY

Hallmarks of CF

  • The pathophysiologic triad includes:

    1. Elevated sodium and chloride concentrations in sweat, saliva, and tears.

    2. Overproduction of mucus leading to airway obstruction.

    3. Pancreatic enzyme deficiency resulting in malabsorption.

  • The clinical manifestations largely stem from thick mucus obstruction and the resultant pancreatic enzyme deficiency.

Mechanisms of Disease

  • Thick mucus precipitates in the excretory ducts leading to obstruction, damaging tissues and organs over time.

  • The impact is evident in:

    • Sweat Glands: Impaired reabsorption of ions, causing sweat to be saltier than normal.

    • Lungs: Chloride transport impairment results in viscous mucus, leading to chronic infections and progressive lung disease.

    • Digestive System: Thickened mucus obstructs pancreatic ducts, leading to malabsorption and digestive issues.

  • This has broader implications for the lifespan and quality of life for patients.

DIAGNOSIS

Clinical Manifestations

  • Diagnosis requires a thorough patient history and physical examination, supported by laboratory testing.

  • Key indicators:

    • Frequent respiratory infections, persistent productive cough, failure to thrive, abdominal pain, and steatorrhea.

  • Typical laboratory tests include:

    • Sweat tests measuring chloride levels.

    • Genetic testing for CFTR mutations.

Diagnostic Approach

  • Newborn screening is mandated in several states. Patients diagnosed early tend to have better nutrition and outcomes. Common screening tests include:

    • Immunoreactive trypsinogen (IRT) levels in newborns.

    • Sweat concentrations (≥60 meq/L consistent with CF).

THERAPY

Current Treatment Options

  • No current cures for CF exist, and treatment focuses on improving symptoms and prolonging life.

  • Key components of management include:

    • Airway Clearance: Techniques such as postural drainage, breathing exercises, and mucolytics (e.g., dornase alfa).

    • Antibiotic Therapy: For infections, particularly with Pseudomonas and Staphylococcus aureus. Inhaled antibiotics like tobramycin are common.

    • Nutritional Support: High-calorie, high-fat diets and pancreatic enzyme replacements, especially for those with pancreatic insufficiency.

  • Lung Transplantation: Considered for advanced cases and can significantly improve quality of life.

Future Directions

  • Gene therapy for CF is still under investigation but faces challenges, such as transient expression of the replaced gene.

PROGNOSIS

Complications and Survival

  • Patients with CF can experience serious complications: pneumonia, respiratory failure, diabetes, and liver disease can accelerate mortality.

  • Life expectancy has improved; patients often reach their mid-30s, and increasingly more are living into their 40s and 50s with proper treatment and care.

  • Most patients create a regimen utilizing medications and lifestyle adjustments to manage symptoms effectively. Successful management can contribute to improved independence and quality of life.

Enjoyable Life Experiences

  • Children with CF can lead normal lives with support and treatments, participating in school and recreational activities. Support from parents emphasizing normality can benefit their social development.

SUGGESTED READINGS

  • Chesnutt MS, Prendergast TJ. Cystic fibrosis. In: McPhee SJ, Papadakis MA, Tierney LM Jr. eds. Current Medical Diagnosis and Treatment.

  • Evers DB, McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children.

  • Mayo Clinic staff. Cystic fibrosis. Available at: www.mayoclinic.com/health/cystic-fibrosis/DS00287.